Amyloid imaging of alzheimer’s disease using pittsburgh compound B

[1]  Keith A. Johnson,et al.  P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.

[2]  William E. Klunk,et al.  IC–103–05: Pittsburgh compound–B four years later: What have we learned, what lies ahead? , 2006 .

[3]  H. Engler,et al.  IC-103-01 PIB amyloid imaging in brain of AD and MCI patients-relation to CSF markers and cognition , 2006, Alzheimer's & Dementia.

[4]  S. DeKosky,et al.  IC-P-016 Imaging of cerebral amyloid angiopathy with Pittsburgh compound B , 2006, Alzheimer's & Dementia.

[5]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[6]  D. Skovronsky,et al.  P2-343 Imaging amyloid with I123 IMPY SPECT , 2006, Alzheimer's & Dementia.

[7]  R. Sperling,et al.  IC–103–04: Amyloid burden correlates with cognitive function in normal aging, MCI and AD , 2006 .

[8]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[9]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[10]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[11]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[12]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[13]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[14]  Rebecca A Betensky,et al.  Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease , 2006, The Journal of Neuroscience.

[15]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[17]  A. Gee,et al.  Delineation of Positron Emission Tomography Imaging Agent Binding Sites on β-Amyloid Peptide Fibrils* , 2005, Journal of Biological Chemistry.

[18]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  N. Relkin,et al.  The immune system, amyloid‐β peptide, and Alzheimer's disease , 2005, Immunological reviews.

[20]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[21]  W. K. Cullen,et al.  Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo , 2005, Nature Medicine.

[22]  A. Gee,et al.  Evidence for the Presence of Three Distinct Binding Sites for the Thioflavin T Class of Alzheimer's Disease PET Imaging Agents on β-Amyloid Peptide Fibrils* , 2005, Journal of Biological Chemistry.

[23]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[24]  J. Morris,et al.  Neuropathologic Criteria for Diagnosing Alzheimer Disease in Persons with Pure Dementia of Alzheimer Type , 2004, Journal of neuropathology and experimental neurology.

[25]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[26]  Edward A. Stern,et al.  Cortical Synaptic Integration In Vivo Is Disrupted by Amyloid-β Plaques , 2004, The Journal of Neuroscience.

[27]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[28]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[29]  B. Hyman,et al.  Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. , 2003, Neuroimaging clinics of North America.

[30]  Bengt Långström,et al.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development , 2003, European Journal of Clinical Pharmacology.

[31]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[32]  V. Kepe,et al.  In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile , 2003, Neuroscience.

[33]  B. Hyman,et al.  In Vivo Multiphoton Imaging of a Transgenic Mouse Model of Alzheimer Disease Reveals Marked Thioflavine‐S‐Associated Alterations in Neurite Trajectories , 2003, Journal of neuropathology and experimental neurology.

[34]  J. Trojanowski,et al.  IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques , 2002, Brain Research.

[35]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[36]  Chester A. Mathis,et al.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.

[37]  G. Small,et al.  Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.

[38]  M. Kung,et al.  Novel stilbenes as probes for amyloid plaques. , 2001, Journal of the American Chemical Society.

[39]  W. Klunk,et al.  X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[40]  Bin Zhang,et al.  In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. , 2000 .

[41]  B. Strooper,et al.  The presenilins in Alzheimer's disease--proteolysis holds the key. , 1999, Science.

[42]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[43]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[44]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[45]  B. Hyman,et al.  The Neuropathological Diagnosis of Alzheimer’s Disease: Clinical-Pathological Studies , 1997, Neurobiology of Aging.

[46]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  D. Selkoe,et al.  Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.

[48]  Glenner Gg.  Alzheimer's disease. The commonest form of amyloidosis. , 1983, Archives of pathology & laboratory medicine.

[49]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[50]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[51]  S. Hirai,et al.  Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.

[52]  T. Spires,et al.  Neuronal Structure is Altered by Amyloid Plaques , 2004, Reviews in the neurosciences.

[53]  K. Jellinger,et al.  Neuropathology of Alzheimer's disease: a critical update. , 1998, Journal of neural transmission. Supplementum.